Capella

Data from exploratory cardiac assessments and post-hoc analyses of safety data in the APOLLO Phase 3 study of patisiran, an RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, were published in the journal Circulation. Read the paper in Circulation...

On September 11, 2018, we hosted an online RNAi Roundtable to review the progress with ONPATTRO™ (patisiran) and ALN-TTRsc02, RNAi therapeutics for the treatment of transthyretin-mediated amyloidosis*. Access the replay View the presentation Read the transcript * ONPATTRO is approved in the U.S. for the polyneuropathy of hereditary ATTR (hATTR) amyloidosis in adults, and in the EU for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. **ALN-TTRsc02 is an investigational RNAi therapeutic, in development for the treatment of ATTR amyloidosis. 

We presented new analyses from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, at the 2018 Peripheral Nerve Society (PNS) Annual Meeting, held July 22-25, 2018 in Baltimore, MD. Read our press release Ajroud-Driss et al. - "Impact of Patisiran on Overall Health Status in hATTR Amyloidosis: Results from the APOLLO Trial" Polydefkis et al. - "Infusion Related Reactions in Patients with hATTR Amyloidosis Treated with Patisiran" Dyck et al. - "Neuropathy Progression in Patients with hATTR Amyloidosis: Analysis of the APOLLO Placebo Arm" Coelho et al. - "Longitudinal Changes in mNIS+7 are Associated with Changes in Ambulatory Status in Hereditary Transthyretin-Mediated Amyloidosis" Coelho et al. - "Indirect Comparison of Patisiran and Tafamidis for Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy" Gonzalez-Duarte et al. - "Changes in Neuropathy Stage in Patients with Hereditary Transthyretin-Mediated Amyloidosis Following Treatment with Patisiran, an Investigational RNAi Therapeutic: An Analysis from the Phase 3 APOLLO Study"

We presented new results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, at the International Congress on Neuromuscular Diseases (ICNMD), held July 6-10, 2018 in Vienna, Austria. Obici et al. – “APOLLO Phase 3...

We are hosting a series of online "RNAi Roundtables" from June through September, at which Alnylam scientists, clinical collaborators, and patients or patient advocates review recent progress in many of the Company's late-stage pipeline programs and discuss the related disease areas.

We presented additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, at the 4th Congress of the European Academy of Neurology (EAN), held June 16-19, 2018 in Lisbon, Portugal. Coelho et al. –...

SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.